Determination of the 90% Effective Dose of Oliceridine Combined with Propofol for Day-Case Hysteroscopy

This study employed probit regression analysis to determine the 90% effective dose (ED₉₀) of oliceridine when combined with propofol for day-case hysteroscopy.

100 patients undergoing hysteroscopic surgery were randomized to receive intravenous oliceridine (0.01, 0.015, 0.02, 0.025, or 0.03 mg kg^-1) 3 minutes preoperatively. Propofol was administered intravenously at 2 mg kg^-1 induction and maintained at 6 mg kg^-1 h^-1. Successful anesthesia was defined as absence of body movement during cervical dilation. Parameters recorded included the success rate, propofol consumption, total surgical duration, recovery time, postoperative pain, and adverse events.

The ED₉₀ of oliceridine for suppressing response to cervical dilation was 0.025 (95% confidence interval, CI, 0.020-0.050) mg kg^-1. The incidence of propofol injection pain in the 0.01, 0.015, 0.02, 0.025, and 0.03 mg kg^-1 oliceridine groups (80%, 80%, 45%, 40%, and 30%, respectively) were significantly different (P = 0.001). There was no difference in the propofol requirements, time to anesthesia emergence, and visual analog scores(VAS) at 30 minutes postoperation among groups. No serious adverse events occurred in any patient.

For healthy adult women undergoing day-case hysteroscopy, oliceridine 0.025 mg kg^-1 combined with propofol provides effective and safe anesthesia.